DISCOVERY PLATFORM

Discovery platform model

To start a project, we work together with the customer to identify the best target gene for the particular indication. If the gene-of-interest is already clear, we can directly move to the next phase of discovery.

For the gene-of-interest, we will next do in silico analysis using our in-house software. RNatives insilico discovery utilizes a broad spectrum of biological data to narrow down the candidates for screening.

Next, we will test the candidates in vitro in our laboratory. We will select a cell culture model that is suitable for the indication and screen the effects of candidates. During the in vitro phase, we can also further develop the formulation, e.g. test different delivery vehicles.

This process allows RNatives to quickly identify novel therapeutic entities for various target genes. After validating the functionality in cell culture, the candidate is ready to be tested in an indication-specific disease model in animals. This phase of the studies can optionally be coordinated by RNatives, as we have good connections to many CROs.

RNatives offers the AI-enhanced saRNA discovery platform for partners in pharmaceutical companies. Together we can utilize the RNatives’ know-how for saRNA design and testing to generate novel RNA therapeutics for various indications. RNatives brings in its team of experts with decades of experience in saRNA biology to offer the full-service discovery platform for partners interested in entering research or discovery collaboration. Projects are planned case-by-case, starting from the target identification and finding the most suitable cell model for initial testing of the saRNAs, all the way to potentially coordinating the proof-of-principle experiments in animal models. RNatives and the partner will agree on project-specific milestones and licensing terms before entering the project.

RNatives is actively seeking pharma company partners that have an interest in finding novel RNA therapy approaches for their R&D pipelines. At RNatives, we are at the forefront of revolutionizing medicine through innovative gene therapy solutions and we are committed to developing novel, cutting-edge methods that transform the lives of patients worldwide. Together we can make this vision into reality.

If you are interested in discussion potential collaboration, please contact us via email or phone:

info@rnatives.com or mikko.turunen@rnatives.com

+358 445537414 (Mikko Turunen, PhD, Founder and CSO)